Shattuck Labs Inc. (STTK): Price and Financial Metrics

Shattuck Labs Inc. (STTK): $4.40

0.24 (-5.17%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add STTK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#196 of 340

in industry

STTK Price/Volume Stats

Current price $4.40 52-week high $11.76
Prev. close $4.64 52-week low $1.33
Day low $4.19 Volume 484,700
Day high $4.69 Avg. volume 416,670
50-day MA $6.10 Dividend yield N/A
200-day MA $6.49 Market Cap 209.22M

STTK Stock Price Chart Interactive Chart >


Shattuck Labs Inc. (STTK) Company Bio


Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.


STTK Latest News Stream


Event/Time News Detail
Loading, please wait...

STTK Latest Social Stream


Loading social stream, please wait...

View Full STTK Social Stream

Latest STTK News From Around the Web

Below are the latest news stories about SHATTUCK LABS INC that investors may wish to consider to help them evaluate STTK as an investment opportunity.

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

AUSTIN, TX and DURHAM, NC, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the pricing of a registered offering of 4,651,163 shares of common stock, par value $0.0001 (the “common stock”), at a price of $6.45 per share, which is pr

Yahoo | December 21, 2023

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Shattuck Labs...

Yahoo | December 21, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning!

William White on InvestorPlace | December 14, 2023

EY Layoffs 2023: What to Know About the Latest EY Job Cuts

EY layoffs have been announced and this has the accounting firm cutting 130 jobs to adjust for slowing demand after the pandemic.

William White on InvestorPlace | December 13, 2023

Why Is Shattuck Labs (STTK) Stock Up 93% Today?

Shattuck Labs stock is rising on Wednesday after the company provided positive initial results from a Phase 1 clinical trial.

William White on InvestorPlace | December 13, 2023

Read More 'STTK' Stories Here

STTK Price Returns

1-mo 5.64%
3-mo -54.07%
6-mo -55.38%
1-year 64.79%
3-year -81.20%
5-year N/A
YTD -38.29%
2023 210.00%
2022 -72.97%
2021 -83.76%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!